Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-armed, Open, Phase I Study of ReT01 ACT Injection in the Treatment of Patients With Advanced Solid Tumors

NCT06257680 is registered in ClinicalTrials.gov with Beijing Xunsheng Biomedical Research Co., Ltd. as lead sponsor.

NCT NCT06257680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06257680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-armed, Open, Phase I Study of ReT01 ACT Injection in the Treatment of Patients With Advanced Solid Tumors
Lead sponsor
Beijing Xunsheng Biomedical Research Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
April 8, 2024
Completion date
February 18, 2027
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor